Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Mr.
Mr.
Candidates for Directors Who Are Not Audit and Supervisory Committee Members |
|||
|
Category |
Expected Role |
|
|
Internal |
Existing |
Representative Director, President & Chief Executive Officer |
|
Internal |
Existing |
Director, President, Research & Development |
|
Internal |
New |
Director, Chief Financial Officer |
|
External |
Existing |
External Director, Chair of the Board Meeting |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
Existing |
External Director |
|
External |
New |
External Director |
The tenure for non- |
Candidates for Directors Who Are Audit and Supervisory Committee Members |
|||
|
Category |
Expected Role |
|
Koji Hatsukawa |
External |
Existing |
|
|
External |
Existing |
|
|
External |
Existing |
|
|
External |
New |
|
The tenure for |
Note:
-
The role of the directors will be determined at the Board of Directors meeting and the
Audit and Supervisory Committee meeting to be held after the 148th Ordinary General Meeting of Shareholders. -
The members of the
Nomination Committee andCompensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 148th Ordinary General Meeting of Shareholders. -
Ms. Asuka Miyabashira, currently head of the Neuroscience Business Unit within JPBU, will assume the role of president of JPBU, effective
April 1, 2024 .
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321811422/en/
Media Contacts:
Global Media
brendan.jennings@takeda.com
+81 80-2705-8259
Source: